BIOMAT Database Logo BIOMAT Database Logo

[Bullous pemphigoid induced by linagliptin]. 2020

N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
Medicina de Familia, Centro de Salud Universitario Los Alpes, Madrid, España. Electronic address: ninfa.casbis@hotmail.com.

UI MeSH Term Description Entries
D010391 Pemphigoid, Bullous A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis. Pemphigoid,Bullous Pemphigoid,Pemphigoids
D003875 Drug Eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. Dermatitis Medicamentosa,Dermatitis, Adverse Drug Reaction,Maculopapular Drug Eruption,Maculopapular Exanthem,Morbilliform Drug Reaction,Morbilliform Exanthem,Drug Eruption,Drug Eruption, Maculopapular,Drug Eruptions, Maculopapular,Drug Reaction, Morbilliform,Drug Reactions, Morbilliform,Eruption, Drug,Eruption, Maculopapular Drug,Eruptions, Drug,Eruptions, Maculopapular Drug,Exanthem, Maculopapular,Exanthem, Morbilliform,Exanthems, Maculopapular,Exanthems, Morbilliform,Maculopapular Drug Eruptions,Maculopapular Exanthems,Morbilliform Drug Reactions,Morbilliform Exanthems,Reaction, Morbilliform Drug,Reactions, Morbilliform Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069476 Linagliptin A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione,1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-,BI 1356,BI-1356,BI1356,Tradjenta,Trajenta,1356, BI
D054873 Dipeptidyl-Peptidase IV Inhibitors Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release. DPP-4 Inhibitor,DPP-4 Inhibitors,DPP-IV Inhibitor,DPP-IV Inhibitors,DPP4 Inhibitor,DPP4 Inhibitors,Dipeptidyl Peptidase 4 Inhibitor,Dipeptidyl-Peptidase 4 Inhibitor,Dipeptidyl-Peptidase IV Inhibitor,Gliptin,Gliptins,Dipeptidyl-Peptidase 4 Inhibitors,DPP 4 Inhibitor,DPP 4 Inhibitors,DPP IV Inhibitor,DPP IV Inhibitors,Dipeptidyl Peptidase 4 Inhibitors,Dipeptidyl Peptidase IV Inhibitor,Dipeptidyl Peptidase IV Inhibitors,Inhibitor, DPP-4,Inhibitor, DPP-IV,Inhibitor, DPP4,Inhibitor, Dipeptidyl-Peptidase 4,Inhibitor, Dipeptidyl-Peptidase IV

Related Publications

N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
Linagliptin-induced bullous pemphigoid.
December 2017, International journal of dermatology,
N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
Atypical Bullous Pemphigoid After Linagliptin Intake.
September 2021, The American journal of case reports,
N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
Linagliptin-Associated Alopecia and Bullous Pemphigoid.
January 2019, European journal of case reports in internal medicine,
N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
Bullous Pemphigoid Associated With Linagliptin Treatment.
February 2016, JAMA dermatology,
N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
[Linagliptin and bullous pemphigoid: the story continues].
January 2020, Semergen,
N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
Linagliptin-associated bullous pemphigoid treated with rituximab.
September 2019, BMJ case reports,
N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
A case of irritant contact dermatitis and suspected linagliptin-induced koebnerized bullous pemphigoid.
April 2020, JAAD case reports,
N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
Bullous pemphigoid induced by vaccination.
July 1996, The British journal of dermatology,
N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
Bullous pemphigoid induced by fluoxetine.
October 1999, The British journal of dermatology,
N Castillo Biscari, and G Mora Navarro, and A Imbernón-Moya, and A Carrasco Sayalero, and S Madero Velázquez
Bullous pemphigoid induced by bumetanide.
March 1998, The British journal of dermatology,
Copied contents to your clipboard!